| Snowflake Score | |
|---|---|
| Valuation | 0/6 |
| Future Growth | 0/6 |
| Past Performance | 0/6 |
| Financial Health | 0/6 |
| Dividends | 0/6 |
Response Oncology, Inc. Competitors
Price History & Performance
| Historical stock prices | |
|---|---|
| Current Share Price | US$0.000001 |
| 52 Week High | US$0.000001 |
| 52 Week Low | US$0.000001 |
| Beta | 0 |
| 1 Month Change | 0% |
| 3 Month Change | n/a |
| 1 Year Change | n/a |
| 3 Year Change | 0% |
| 5 Year Change | n/a |
| Change since IPO | -100.00% |
Recent News & Updates
No updates
Recent updates
No updates
Shareholder Returns
| ROIX | US Healthcare | US Market | |
|---|---|---|---|
| 7D | 0% | -2.3% | -0.7% |
| 1Y | n/a | 0.6% | 22.8% |
Return vs Industry: Insufficient data to determine how ROIX performed against the US Healthcare industry.
Return vs Market: Insufficient data to determine how ROIX performed against the US Market.
Price Volatility
| ROIX volatility | |
|---|---|
| ROIX Average Weekly Movement | n/a |
| Healthcare Industry Average Movement | 7.4% |
| Market Average Movement | 6.1% |
| 10% most volatile stocks in US Market | 16.7% |
| 10% least volatile stocks in US Market | 3.0% |
Stable Share Price: ROIX has not had significant price volatility in the past 3 months.
Volatility Over Time: Insufficient data to determine ROIX's volatility change over the past year.
About the Company
| Founded | Employees | CEO | Website |
|---|---|---|---|
| 1984 | n/a | Charles Sweet | n/a |
Response Oncology, Inc. does not have significant operations. The company, along its wholly owned and majority owned subsidiaries, operated as a comprehensive cancer management company. As of May 20, 2002, the company has liquidated substantially all of its operating assets and anticipates that the remaining assets would be liquidated and all wind-down activities completed by the end of 2002.
Response Oncology, Inc. Fundamentals Summary
| ROIX fundamental statistics | |
|---|---|
| Market cap | US$12.00 |
| Earnings (TTM) | -US$51.09m |
| Revenue (TTM) | US$109.32m |
0.0x
P/S Ratio0.0x
P/E RatioIs ROIX overvalued?
See Fair Value and valuation analysisEarnings & Revenue
| ROIX income statement (TTM) | |
|---|---|
| Revenue | US$109.32m |
| Cost of Revenue | US$85.29m |
| Gross Profit | US$24.04m |
| Other Expenses | US$75.12m |
| Earnings | -US$51.09m |
Last Reported Earnings
Mar 31, 2002
Next Earnings Date
n/a
| Earnings per share (EPS) | 0 |
| Gross Margin | 0.00% |
| Net Profit Margin | 0.00% |
| Debt/Equity Ratio | 0.0% |
How did ROIX perform over the long term?
See historical performance and comparison